Firalis S.A. and Celemics, Inc. announce an agreement for the commercialization of a unique proprietary long non-coding RNA (lncRNA) panel, FiMICS®. The precise quantification of 3233 cardiac-enriched lncRNAs in peripheral blood samples would better characterize patients with diverse cardiac disorders and toxicities. France, Huningue, 19th, September 2018 Firalis S.A. (“Firalis”), a Huningue based developer and…Read more
Recent Posts by admin
New matrices validated on the BIOPRED panel Whole Blood EDTA & PBMC cells Now Available! After the launch of our Biopred panel this year, Firalis is proud to announce the validation of new matrices during this Summer. Recently, Firalis Group has developed a mRNA targeted gene sequencing panel, allowing to quantify 2155 mRNAs in whole blood from…Read more
FIRALIS S.A. announces the launch of the Biopred panel, an innovative RUO product that profiles thousands of mRNAs associated with inflammatory autoimmune disorders via a pioneering targeted mRNA profiling technology without RNA extraction. France, Huningue, 23th May 2018 Firalis S.A (“Firalis”), a developer of biomarker-based products and provider of biomarker services announced the release of…Read more
Firalis is certified Propel by Illumina for Next-Generation Sequencing (NGS) best practices To ensure the quality of Next-Generation Sequencing services, Firalis recently obtained the Propel Certification from Illumina. This new certification is based on compliance with the Good Laboratory Practices, production of high quality sequencing data and on the qualification of operators of the Illumina…Read more
Recent Comments by admin
No comments by admin yet.